OptiNose

OptiNose — Jefferies Healthcare Conference 2019

20 slides from OptiNose's conference presentation, Jun 4, 2019

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Exhibit 99.1 Building a Leading ENT / Allergy Specialty Company Corporate Presentation June 4, 2019

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu

  3. Slide 3: Building a Leading ENT/Allergy Specialty Company

    Building a Leading ENT/Allergy Specialty Company 3

  4. Slide 4: Chronic Rhinosinusitis is an Attractive Market for XHANCE with High Unmet Need

    Chronic Rhinosinusitis (CRS) is an Attractive Market for XHANCE…with High Unmet Need High Burden 30 Million US Adults suffer from CRS • Disease persists for many years and up to 10 million • Significant quality of life impact of them have nasal (comparable to CHF, COPD, Angina) polyps (NP) 9.75 Mill

  5. Slide 5: Breakthrough Approach to Nasal Delivery

    Breakthrough Approach to Nasal Delivery SOLVES A KNOWN MEDICAL PROBLEM WITH A UNIQUE APPROACH Problem: Solution: Nasal sprays and aerosols do not effectively place drug Unique new concept for delivery gets medicine where it high and deep in the nasal passages needs to be to work Drug Proprietary exh

  6. Slide 6: Optinose EDS Can Deliver Drug High & Deep in the Nose

    Optinose EDS Can Deliver Drug High & Deep in the Nose KEY TO TREATING CRS (W OR W/OUT POLYPS) Optinose EDS w/Exhalation Sinus drainage regions are key treatment targets Nasal Spray w/o Exhalation Intranasal steroids are TOPICALLY ACTING medications: Delivery to sites of chronic inflammation and nasa

  7. Slide 7: Differentiated Clinical Profile

    Differentiated Clinical Profile Global Clinical Program Key Highlights Trial Type N Sites Significant benefit on all four defining symptoms of CS Phase 3 323 54 NAVIGATE I pivotal Similar improvements in patients with and without nasal polyps Phase 3 323 38 NAVIGATE II Pivotal “Medical” polyp elimin

  8. Slide 8: XHANCE Launch Update

    XHANCE Launch Update optinose_

  9. Slide 9: Examples of Positive XHANCE Physician Feedback

    Examples of Positive XHANCE Physician Feedback* *Testimonials and images reflect real life experience of those who have reported using XHANCE. However, they are individual results and results do vary. We do not claim that they are typical results that users will generally achieve. 9

  10. Slide 10: Encouraging Feedback From Xperience Patient Survey

    Encouraging Feedback From Xperience Patient Survey Patient Responses Prior to Month 2 Refill Total Prior User of Prior User Respondents Flonase / Nasonex Budesonide Rinse (N=2,733) (n=820) (N=175) Patient Satisfaction 89% 90% 90% Experience Symptom Improvement 80% 79% 68% Prefer XHANCE 77% 82% 83% R

  11. Slide 11: Key Levers to Continue to Drive XHANCE Growth

    Key Levers to Continue to Drive XHANCE Growth Continued Execution of Strategy (Defined Appropriate Patient Type, Enhanced Efficacy Message & Affordability Program) Sales Force Expansion 7-Day Samples Increase Payer Coverage Direct to Consumer Pilot 11

  12. Slide 12: Deployed Territory Managers to New Territories, Now Promoting XHANCE in 100 Territories

    Deployed Territory Managers to New Territories in April and now Promote XHANCE in 100 Territories Total Albany, NY Albuquerque, NM NEW Baltimore, MD Boston, MA Charleston, SC Columbia, SC Detroit (South), MI Dothan, Al Fort Wayne, IN Grand Rapids, MI Greenville, SC Huntington, WV Jackson, MS Knoxvil

  13. Slide 13: XHANCE Prescription Volume Grew 59% in Q1 2019 versus Q4 18

    XHANCE Prescription Volume Grew 59% in Q1 2019 versus Q4 2018 Continued growth in Q1 2019 driven by promotional materials and patient affordability program rolled out in August/September 2018 XHANCE TRx +59% 25,000 22,490 +50% 20,000 15,000 14,106 9,427 10,000 8,611 5,000 0 Q2 '18 Q3 '18 Q4 '18 Q1 '

  14. Slide 14: XHANCE Prescription Volume Grew 19% in April 2019 versus March 2019

    XHANCE Prescription Volume Grew 19% in April 2019 versus March 2019 April Prescription Trends Aligned with Q4 2018 and Q1 2019 Growth Rates XHANCE TRx +19% 11,000 10,431 10,000 +18% 9,000 8,756 +18% 8,000 7,442 7,000 6,292 6,000 5,000 January February March April 2019 2019 2019 2019 TRx for Intranas

  15. Slide 15: Chronic Sinusitis Trials Update

    Chronic Sinusitis Trials Update

  16. Slide 16: XHANCE Chronic Sinusitis Indication (sNDA) Studies

    XHANCE Chronic Sinusitis Indication (sNDA) Study 3205 - ClinicalTrials.gov Identifier: NCT03781804 . 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study . First patient enrolled in Q4 2018 . Estimated enrollment: 378 patients . Focused on successful execution of s

  17. Slide 17: Closing Remarks

    Closing Remarks optinose_

  18. Slide 18: Optinose Key Priorities

    Optinose Key Priorities Continue to drive XHANCE® prescription growth Advance our XHANCE clinical program for a follow-on indication for the treatment of Chronic Sinusitis Support our commercial and development objectives through efficient use of capital ■ $171 Million of cash as of March 31, 2019 1

  19. Slide 19: Investor Relations

    Investor Relations – NASDAQ: OPTN 1 At 31 March 2019: Analyst Coverage – $171 million in cash – Long-term debt: $75 million BMO: Gary Nachman – 41.3 million common shares o/s – 9.6 million options & warrants o/s Jefferies: David Steinberg Cantor Fitzgerald: Brandon Folkes Optinose Investor Contact J

  20. Slide 20: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Corporate Presentation June 4, 2019

OptiNose — Jefferies Healthcare Conference 2019 on 6ix